Welcome! The Bloomington Life Sciences Partnership is a collaborative effort dedicated to continued life sciences business growth in greater Bloomington, Indiana - a nationally recognized leading metro area in medical devices, contract pharma, biotechnology, basic research and life sciences workforce development.
Translational Research Pilot Grant Program
Feb11

Translational Research Pilot Grant Program

To All IUB Faculty Members:   The Johnson Center for Innovation and Translational Research is pleased to announce the second year of Translational Research Pilot Grants. This pilot grant program has been established to fund the completion of proof of concept projects that support the development of research projects with industry partners, the establishment of new companies, or strengthen patent applications based on IUB discoveries.   Eligible Projects   All projects in any discipline directly related to moving IUB research or scholarly activities closer to commercialization are eligible. Projects must be based on discoveries that have been submitted to the IURTC in the form of an Invention Disclosure (http://iurtc.iu.edu/forms/index.shtml). Project proposals may be submitted by any IUB faculty member. Project budgets up to $25,000 will be considered and can be used to support research in the Principal Investigators laboratory, or for purchased services from IU core facilities or external vendors.   Proposal Reviews   Pilot Grant applications will be assessed for their scientific merit, the potential to significantly enhance the commercial development of the new discovery, and the potential for the creation of new intellectual property.   Application Due Date   April 1, 2016 Funding will be available June 1, 2016   Instructions for applying can be accessed on the JCEB website: http://jcitr.indiana.edu/opportunities.shtml   We are available to meet with you to discuss potential projects and assist with the filing of the Invention Disclosure. We encourage you to take advantage of this new funding opportunity!   Regards, Keith   Keith R. Davis, Ph.D. Director The Johnson Center for Innovation and Translational Research Simon Hall, Room 100A 212 S. Hawthorne Drive Indiana University, Bloomington, IN 47405 Office: 812-856-4805 Email: keirdavi@indiana.eduJCITR   For more information, see Pilot Grant Program...

Read More
Biosciences Institute Adds Research Fellow
Jan28

Biosciences Institute Adds Research Fellow

INDIANAPOLIS – The Indiana Biosciences Research Institute has named its first Indiana Research Fellow. Indiana University Center for Diabetes and Metabolic Diseases Director Raghu Mirmira will also serve as the institute’s interim scientific director. Mirmira is also a professor of pediatric diseases, director of IU’s Herman B. Wells Center’s Pediatric Diabetes Research Group and director of the Medical Scientist Training Program for M.D. and Ph.D. students. He earned his bachelor’s, M.D. and Ph.D. degrees from the University of Chicago. As part of his new role with IBRI, he will work with Chief Executive Officer David Broecker to recruit additional research scientists, set up research operations and begin project work. Broecker calls Mirmira a “unique and talented researcher with a track record of building nationally-recognized research centers.” The $360 million institute was launched in 2013, through a partnership among private sector companies, academic institutions and the state of Indiana. Funding has come from companies and organizations including Eli Lilly and Co. (NYSE: LLY), Dow AgroSciences, Lilly Endowment Inc., Roche Diagnostics and Indiana University Health. The state has targeted the planned 60-acre 16 Tech innovation district as a permanent location for the institute. To read more on this, visit Inside Indiana Business or the Indiana Biosciences Research...

Read More
Johnson Center for Innovation and Translational Research announces new name, expanded mission
Nov20

Johnson Center for Innovation and Translational Research announces new name, expanded mission

FOR IMMEDIATE RELEASE BLOOMINGTON, Ind. — A monthslong effort to shift the Johnson Center for Entrepreneurship in Biotechnology’s mission is complete, as it now boasts a new name, a broader base of campus constituents and an updated website. The organization is now known as the Johnson Center for Innovation and Translational Research, or JCITR. The new name was approved by the Indiana University Board of Trustees in October and recently made official by President Michael A. McRobbie, said Keith R. Davis, the center’s director. The move not only addressed a need to lessen confusion with its cross-campus counterpart, the Johnson Center for Entrepreneurship and Innovation at the Kelley School of Business. It also reflects an expanded mission to serve all schools, departments and disciplines throughout the Bloomington campus, rather than only those ventures related to biotechnology or other fields within the College of Arts and Sciences. Yet JCITR’s core directive is unchanged. It aims to boost the participation of faculty, researchers and students in translational research and the commercialization of research discoveries by working with industry partners and creating new companies. “Our new name truly captures the core focus of our mission to enhance innovation across the Bloomington campus and will provide an identity for our unique position within IU’s research community,” Davis said. “We hope faculty will come to recognize JCITR as the place where they can get hands-on assistance with building a translational research program and commercializing their discoveries.” Vice Provost for Research Rick Van Kooten said the move reinforces IU’s commitment through its Bicentennial Strategic Plan to build a prosperous and innovative Indiana, in part by establishing a culture of “building and making” statewide. “I am truly excited that the expertise of the Johnson Center is now broadening to encompass the entire Bloomington campus,” Van Kooten said. “Innovation and translational research are key drivers of research excellence. The skills and services offered through JCITR are invaluable to IU researchers, particularly as we move forward with our Grand Challenges program and a new Emerging Areas of Research program.” Members of JCITR’s staff, or “discovery team,” work to make it easy and efficient for faculty to bring their ideas or inventions to market while continuing to focus on their core strengths in basic research. Such duties include: Working with faculty to identify current and new research that can attract commercial contracts or be translated into products that may lead to the launch of Spin Up companies or startup ventures; Collaborating with the IU Research and Technology Corp. and Office of Research Administration to help faculty submit grant applications; Identifying industry partners and negotiating industry contracts in concert with...

Read More
Novo Nordisk to acquire Calibrium LLC and MB2 LLC
Aug28

Novo Nordisk to acquire Calibrium LLC and MB2 LLC

Acquisition expands Novo Nordisk’s portfolio of projects within diabetes and obesity Bagsværd, Denmark, 27 August 2015 – Novo Nordisk today announced that it has entered into a definitive agreement under which Novo Nordisk will acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies based in Indiana, US. Formed in 2013 and 2014, respectively, Calibrium and MB2 are focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. The acquisition will expand Novo Nordisk’s portfolio of projects and intellectual property rights within diabetes and obesity and provide a basis for expanding Novo Nordisk’s research presence in the US. Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk says: “We are always on the lookout for ways to strengthen our leadership position within therapeutic proteins. This research team has demonstrated world-class capabilities in protein design and created a project portfolio of innovative product leads that fit very well with our aspirations within diabetes and obesity.” Dr Richard DiMarchi, chief scientific officer and co-founder of Calibrium and MB2 says: “It’s an honour to join the global Novo Nordisk research community. Their intense focus on metabolic diseases, which over the years has led to numerous breakthrough proteinbased medicines, aligns perfectly with my career-long priorities. I’m optimistic that together we can create novel, transformative therapies in the fight against the global epidemic of diabetes and obesity.” The parties have agreed not to disclose the financial details of the transactions. The closing of the transaction is subject to US regulatory approval and is expected to occur during the third quarter of 2015.   About Calibrium and MB2 Calibrium is an emerging biopharmaceutical company focused on the discovery and early development of novel peptides for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, chief executive officer, and Richard DiMarchi, PhD, chief scientific officer. MB2 is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class, mixed agonist drugs for the treatment of diabetes and obesity. MB2 was co-founded by Kent Hawryluk, chief executive officer and Richard DiMarchi, PhD, chief scientific officer. Both companies are privately held and located in Carmel, IN, US. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn,...

Read More
Sintact Medical Systems Receives NSF SBIR Grant
Aug12

Sintact Medical Systems Receives NSF SBIR Grant

Phase I grant will advance development of Sintact’s surgical film, which prevents internal scar formation Bloomington, IN – August 12, 2015 – Sintact Medical Systems, a startup developing an implantable film that prevents internal scar formation following surgery, announced today that the company was selected for a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant. In addition to the $150,000 Phase I grant, Sintact was awarded $50,000 in matching funds from Elevate Ventures in partnership with the Indiana Economic Development Corporation (IEDC).   The collective funds will contribute to the company’s ongoing testing and development of a non-resorbable film designed to separate and protect internal organs from scar formation and scar-related defects—complications that frequently occur after a number of common surgeries.   “It’s exciting to get this kind of validation and support from an organization like the NSF SBIR program, not to mention the additional contribution from Elevate Ventures and the IEDC,” said Sintact CEO Erik Robinson. “These organizations have provided an incredible opportunity that will enable us to make substantial progress toward bringing our technology to market and ultimately improving patients’ lives.”   Phase I of the NSF SBIR grant program is designed as a “proof-of-concept” grant, which can be followed by a larger development grant of $750,000. For the initial phase, Sintact plans to conduct a three-month animal study—a longer version of a study Robinson performed during his doctoral work at Northwestern University in collaboration with Ann & Robert H. Lurie Children’s Hospital of Chicago, which demonstrated a reduction in scar formation of 86 percent.   In addition to seeking out grant funding, Robinson has advanced the commercialization of Sintact’s technology by participating in various programs that support startups, which he feels ultimately helped them secure the grant.   “We’ve been fortunate to get involved in a number of programs that exist to support companies like ours, and these have been an invaluable resource,” Robinson said. “Not only have they helped connect us to mentors, investors and experts in our field who have been instrumental in our growth, but they’ve also helped position us as an attractive investment and a strong candidate for grants like this one.”    Sintact was a member of the 2014 class of Health Wildcatters, a Dallas-based healthcare startup accelerator program. The company has also been supported by VentureWell, an organization out of Massachusetts that helps commercialize innovations developed at colleges and universities, and iBIO Institute’s PROPEL Center, a Chicago-based effort to increase success rates of life science startups.     “It’s wonderful to see Sintact making such great progress since the program,” said Health Wildcatters CEO Hubert Zajicek. “They have...

Read More